Richard E. Peschel, MD, PhD
Professor, Department of Therapeutic Radiology
 |
richard.peschel@yale.edu Phone: 203.785.2958 Appt Phone: Fax: 203.785.4622 Yale University School of Medicine Department of Therapeutic Radiology Hunter Radiation Therapy Center P.O. Box 208040 New Haven, Connecticut 06520-8040 |
Degrees/Education :
B.S., (with distinction), University of Wisconsin (1968)
Ph.D., Yale University, Nuclear Physics (1975)
M.D., Yale University School of Medicine (1977)
Faculty Appointments:
Assistant Professor, Yale University School of Medicine, Therapeutic Radiology (1981-86)
Associate Professor, Yale University School of Medicine, Therapeutic Radiology (1986-91)
Professor, Yale University School of Medicine, Therapeutic Radiology (1991-present)
Medical Director, Lawrence & Memorial Hospital, Radiation Oncology (1995-2003)
Medical Director, Lawrence & Memorial Hospital Cancer Center (2003-present)
Certifications/Honors:
2002-2003, Chairman, Scientific Review Panel, Prostate Cancer Research Program: Phsyical Imaging. Congressionally Directed Medical Research Programs.
2001, Chairman, Ad Hoc Committee, Breast Cancer Research Program: Physical Imaging. Congressionally Directed Medical Research Programs.
2000, AMA Ethics Standards Division, American Medical Association, American Medical Association, Ethics in Medicine.
Funding – Anna Fuller Foundation: IMRT and Intensity Guided IMRT – complications, $250,000, from 2006 to 2008.
Clinical Interests:
General radiation therapy; bladder cancer; testicular cancer; prostate cancer; intensity modulated radiation therapy (IMRT); brachytherapy; lung cancer; lymphoma; breast cancer; melanoma; testes cancer; prostate cancer; renal cancer.
Research Interests:
Prostate cancer is now the most common malignancy diagnosed in American males and the second leading cause of cancer deaths. Although a variety of approaches (observation, surgery, external beam radiation therapy, brachytherapy, and hormone therapy) are available for prostate cancer, a review of the historical prostate cancer data provides little evidence that the most cost-effective and efficacious therapies are being utilized. The prostate specific antigen (PSA) has revolutionized our understanding of the proper diagnosis and treatment of prostate cancer.
The clinical research programs at the Hunter Radiation Therapy Center include programs to scientifically evaluate the efficacy of surgery versus various forms of radiation therapy including implant therapy, three-dimensional conformal external beam radiation therapy, and intensity modulated radiation therapy (IMRT) for treatment of early prostate cancer. IMRT represents the newest form of radiation therapy for prostate cancer. We are using IMRT with dose escalation for all of our prostate cancer patients. We have recently received a grant from the Anna Fuller Foundation to evaluate the clinical outcomes using IMRT and a new technology called image-guided IMRT.
I wish to be contacted by interested students (medical, graduate or undergraduates) as a potential research mentor/thesis advisor.
Selected PubMed article listing
Training:
Medical School: Yale University School of Medicine, M.D. (1977)
Post Doctoral: Yale University, Nuclear Physics, Ph.D. (1975)
Residency: Yale University School of Medicine, Therapeutic Radiology (1978-80)
Board Certification: Radiation Oncology, Board Certified (1982)
